We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ODT

News List

Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement contractpharma
August 11, 2021
Novel formulation of glycopyrrolate will use Catalent’s Zydis ODT delivery technology for adjunctive therapy for the treatment of peptic ulcer.
SPI Pharma Launches UltraBurst contractpharma
July 13, 2021
SPI Pharma has introduced UltraBurst, providing a step-change in the most critical orally disintegrating tablet (ODT) characteristics—dissolution time. It is an innovative excipient platform for flash ODTs, enabling disintegration in under ten seconds.
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis ODT americanpharmaceuticalreview
December 04, 2018
Biohaven announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy ......